For more than three decades, postoperative chemotherapy—initially fluoropyrimidines and
more recently combinations with oxaliplatin—has reduced the risk of tumor recurrence and …

Colorectal cancer (CRC) is one of the most prevalent cancers, with more than one million
new cases every year. In the last few decades, several advancements in therapeutic and …

Simple Summary In patients with stage III colon cancer, adjuvant chemotherapy with a
fluoropyrimidine combined with oxaliplatin reduces the risk of recurrence and mortality, with …

Since the MOSAIC study, oxaliplatin-based adjuvant chemotherapy has been the standard
treatment of stage III colon cancer. Combination therapy with fluoropyrimidines and …

Simple Summary Stage II colon cancer is defined as an early stage of the tumor disease,
without the involvement of lymph nodes or distant organs. In this group of patients, surgery …

Colorectal cancer (CRC) is a high burden disease with several genes involved in tumor
progression. The aim of the present study was to identify, generate and clinically validate a …

Background Accurate estimation of the long-term risk of recurrence in patients with non-
metastatic colorectal cancer (CRC) is crucial for clinical management. Histology-based deep …

Adjuvant chemotherapy is considered for patients with stage II colorectal cancer (CRC)
characterized by poor prognostic clinicopathological features; however, current stratification …

Colorectal cancer (CRC) is a leading cause of cancer deaths worldwide. CRC develops as a
consequence of genomic instability, characterized by various genetic and epigenetic …

Abstract Development of colorectal cancer occurs via a number of key pathways, with the
clinicopathological features of specific subgroups being driven by underlying molecular …